Long-term follow-up after EDIT-301 gene therapy
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received an infusion of the study drug EDIT-301 as part of a previous clinical trial.
- You (or your parent or guardian) must be willing to sign a consent form agreeing to join this long-term follow-up study.
- You cannot still be actively participating in the main EDIT-301 treatment study — you must have finished that part and be eligible for long-term follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study tests an experimental gene therapy called YOLT-204 for people with sickle cell disease or thalassemia. It aims to see if the treatment is safe and can help reduce symptoms, and participants will be followed long-term.
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
This study is for people who have already received BEAM-101 in a previous study. It simply follows them over time to track their health and any long-term effects.
This trial tests a new gene therapy that may help people with severe sickle cell disease by editing their own blood stem cells to produce healthy red blood cells. It aims to reduce painful crises and other complications.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.